Ugur Keklikci1,2, Sevda I Soker3, Yildirim B Sakalar4, Kaan Unlu4, Selver Ozekinci5, Selcuk Tunik3. 1. Department of Ophthalmology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. ukeklikci@yahoo.com. 2. Department of Ophthalmology, Faculty of Medicine, Dicle University, Diyarbakir, TR-21280, Turkey. ukeklikci@yahoo.com. 3. Department of Histology and Embryology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. 4. Department of Ophthalmology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey. 5. Department of Pathology, Faculty of Medicine, Dicle University, Diyarbakir, Turkey.
Abstract
PURPOSE: To evaluate the efficacy of topical cyclosporin A 0.05% in managing the symptoms of severe vernal keratoconjunctivitis (VKC). METHODS: Fifty-four children with severe VKC were included in this study. All 54 patients were treated with topical cyclosporin A (CsA) 0.05% for 3 months. Ocular signs and symptoms were scored in all patients at entry and after 3 months. Conjunctival impression cytology specimens were examined on the day of enrollment and at the end of the treatment period. RESULTS: The mean scores for severity of signs and symptoms significantly decreased after 3 months compared with those at entry (P<0.001). The density of inflammatory cells in the conjunctival impression cytology specimens decreased significantly. No side effects of the treatment with CsA 0.05% eyedrops were observed. CONCLUSIONS: Topical CsA 0.05% eyedrops were found to be safe and effective in the treatment of patients with VKC. Consistent with these results, topical CsA may efficiently reduce conjunctival inflammation in severe VKC.
PURPOSE: To evaluate the efficacy of topical cyclosporin A 0.05% in managing the symptoms of severe vernal keratoconjunctivitis (VKC). METHODS: Fifty-four children with severe VKC were included in this study. All 54 patients were treated with topical cyclosporin A (CsA) 0.05% for 3 months. Ocular signs and symptoms were scored in all patients at entry and after 3 months. Conjunctival impression cytology specimens were examined on the day of enrollment and at the end of the treatment period. RESULTS: The mean scores for severity of signs and symptoms significantly decreased after 3 months compared with those at entry (P<0.001). The density of inflammatory cells in the conjunctival impression cytology specimens decreased significantly. No side effects of the treatment with CsA 0.05% eyedrops were observed. CONCLUSIONS: Topical CsA 0.05% eyedrops were found to be safe and effective in the treatment of patients with VKC. Consistent with these results, topical CsA may efficiently reduce conjunctival inflammation in severe VKC.
Authors: Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov Journal: Exp Eye Res Date: 2021-01-21 Impact factor: 3.467